| Carol Ann Vicinanza Adami, MD | |
|
2815 S Seacrest Blvd, Attention: Betsy Cox, Boynton Beach, FL 33435-7934 | |
| (561) 736-1200 | |
| (561) 742-1919 |
| Full Name | Carol Ann Vicinanza Adami |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 36 Years |
| Location | 2815 S Seacrest Blvd, Boynton Beach, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154395119 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | ME61707 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Outpatient Services Inc | 6002807385 | 148 |
News Archive
Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Ethnic Tibetan communities in Nepal's highlands are rapidly shrinking as more parents send their children away for a better education and modern careers, a trend that threatens to create a region of graying ghost towns at the top of the world, according to a study that includes Dartmouth College.
Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.
› Verified 8 days ago
| Entity Name | Radiology Associates Of South Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699759183 PECOS PAC ID: 5799689659 Enrollment ID: O20031121000573 |
News Archive
Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Ethnic Tibetan communities in Nepal's highlands are rapidly shrinking as more parents send their children away for a better education and modern careers, a trend that threatens to create a region of graying ghost towns at the top of the world, according to a study that includes Dartmouth College.
Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.
› Verified 8 days ago
| Entity Name | Bethesda-ct Scan Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376588731 PECOS PAC ID: 4284521071 Enrollment ID: O20040304000725 |
News Archive
Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Ethnic Tibetan communities in Nepal's highlands are rapidly shrinking as more parents send their children away for a better education and modern careers, a trend that threatens to create a region of graying ghost towns at the top of the world, according to a study that includes Dartmouth College.
Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.
› Verified 8 days ago
| Entity Name | Baptist Outpatient Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437127529 PECOS PAC ID: 6002807385 Enrollment ID: O20040527000618 |
News Archive
Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Ethnic Tibetan communities in Nepal's highlands are rapidly shrinking as more parents send their children away for a better education and modern careers, a trend that threatens to create a region of graying ghost towns at the top of the world, according to a study that includes Dartmouth College.
Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.
› Verified 8 days ago
| Entity Name | Mori Bean And Brooks Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093782070 PECOS PAC ID: 8820077878 Enrollment ID: O20040714001317 |
News Archive
Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Ethnic Tibetan communities in Nepal's highlands are rapidly shrinking as more parents send their children away for a better education and modern careers, a trend that threatens to create a region of graying ghost towns at the top of the world, according to a study that includes Dartmouth College.
Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carol Ann Vicinanza Adami, MD 2837 Westview Trl, Park City, UT 84098-6251 Ph: (954) 801-8106 | Carol Ann Vicinanza Adami, MD 2815 S Seacrest Blvd, Attention: Betsy Cox, Boynton Beach, FL 33435-7934 Ph: (561) 736-1200 |
News Archive
Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
Ethnic Tibetan communities in Nepal's highlands are rapidly shrinking as more parents send their children away for a better education and modern careers, a trend that threatens to create a region of graying ghost towns at the top of the world, according to a study that includes Dartmouth College.
Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.
› Verified 8 days ago
Alfred Sem, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2815 S Seacrest Blvd, Attention: Betsy Cox, Boynton Beach, FL 33435 Phone: 561-736-1200 Fax: 561-742-1919 | |
Dr. David Dahlenburg, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 2815 S Seacrest Blvd, Boynton Beach, FL 33435 Phone: 561-737-7733 | |
Dr. Valerie D'aurora, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2815 S. Seacrest Blvd, Boynton Beach, FL 33435 Phone: 551-208-6680 | |
Fred Tow, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 8921 Raven Rock Ct, Boynton Beach, FL 33473 Phone: 941-356-2266 | |
Ariana Alvarez, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2815 S Seacrest Blvd, Attention Betsy Cox, Boynton Beach, FL 33435 Phone: 561-736-1200 Fax: 561-742-1919 | |
Richard Edelstein, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2815 S Seacrest Blvd, Attention: Betsy Cox, Boynton Beach, FL 33435 Phone: 561-736-1200 Fax: 561-742-1919 |